Which predicts survival better: shrinking the tumor or clearing the lymph nodes?
NCT ID NCT07557316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 100 adults with advanced rectal cancer who received total neoadjuvant therapy (a combination of chemotherapy and radiation before surgery). Researchers want to see whether the response in the lymph nodes or the primary tumor better predicts how long patients stay cancer-free and survive overall. The goal is to improve how doctors assess treatment success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag University
Sohag, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- A new radiation combo may spare the rectum in early cancer
- Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
- Metabolic MRI may reveal hidden cancer responses and spare patients from surgery
- Can a beetroot drink spot dangerous surgical leaks before they turn deadly?